113 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
, medical affairs, market access), manufacturing, and pipeline. Cintia holds a Doctorate in Pharmacy and Biochemistry from the University of Sao Paulo
8-K
EX-99.1
fnfhw8kt5v92too2t
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-10.4
hriwrq sh
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
5vx1uy
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
nayzjygm
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
ckk 36mhsyaiczfmx
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
dtfiovwn x1ses
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
5tfhrw3 z2qhehbfwe
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
3ic5q 0wo
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
fuxm22dl4g7m
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
qx9u9w2a
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.1
zmh7btwns9jphtw4fq
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am